-
公开(公告)号：EP2572705A1
公开(公告)日：2013-03-27
申请号：EP12198042.9
申请日：2008-09-30
IPC分类号： A61K9/00 , A61K9/20 , A61K31/551 , A61K31/422 , A61K31/4178
CPC分类号： A61K31/4196 , A61K9/0007 , A61K9/0056 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2072 , A61K9/2095 , A61K31/4178 , A61K31/422 , A61K31/519 , A61K31/551 , A61K31/5513
摘要： This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.
摘要翻译： 本发明涉及通过直接压制干燥粉末状混合物而得到的口腔崩解片剂，所述混合物包含至多15重量％的硅酸钙，至少50重量％的稀释剂，崩解剂和活性成分。 它还涉及通过均匀混合粉末形式的特定赋形剂和随后直接压制混合物来制备片剂的方法。 所述片剂在口腔中快速崩解，特别是在不到15秒钟内。
-
2.发明公开Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide 审中-公开的4“的药物组合物 - [（1,4'-二甲基-2'-丙基[2,6'-双-1H-苯并咪唑] -1'-基）甲基] - [1,1'-联苯] - -2-羧酸和6-氯-3,4-二氢-2H-1,2,4-苯并噻二嗪-7-磺酰胺-1,1-二氧化物
公开(公告)号：EP2612658A1
公开(公告)日：2013-07-10
申请号：EP12150321.3
申请日：2012-01-05
IPC分类号： A61K9/20 , A61K31/4184 , A61K31/54 , A61K45/06
CPC分类号： A61K31/4184 , A61K9/209 , A61K31/549 , A61K2300/00
摘要： This invention relates to stable solid immediate release pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid, also known as telmisartan and hydrochlorothiazide (HCTZ or HCT), a thiazide diuretic, which also affords dosage uniformity; process thereof and their use in the treatment of hypertension and essential hypertension.
摘要翻译： 本发明涉及4“的稳定的固体立即释放药物组合物 - [（1,4'dimethyl -2'-丙基[2,6'-双-1H-苯并咪唑] -1'-基）甲基] - [1， 1,1'-联苯] -2-羧酸，即称为替米沙坦和氢氯噻嗪（HCTZ或HCT），噻嗪类利尿剂，其因此得到剂量均匀性; 过程，以及它们在治疗高血压和原发性高血压的治疗。
-
公开(公告)号：EP2572705B1
公开(公告)日：2017-09-13
申请号：EP12198042.9
申请日：2008-09-30
IPC分类号： A61K9/00 , A61K9/20 , A61K31/551 , A61K31/422 , A61K31/4178
CPC分类号： A61K31/4196 , A61K9/0007 , A61K9/0056 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2072 , A61K9/2095 , A61K31/4178 , A61K31/422 , A61K31/519 , A61K31/551 , A61K31/5513
摘要： This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.
摘要翻译： 本发明涉及一种通过直接压制干粉状混合物获得的口腔崩解片剂，所述混合物包含高达15重量％的硅酸钙，至少50重量％的稀释剂，崩解剂和活性成分。 它还涉及通过将粉末形式的特定赋形剂均匀混合并随后直接压制混合物来制备片剂的方法。 所述片剂在口腔中快速崩解，特别是在不到15秒的时间内崩解。
-
4.发明公开Pharmaceutical compositions of (+)-(s)-2-(3-benzoylphenyl)propionic acid tromethamine salt 审中-公开（+） - （s）-2-（3-苯甲酰基苯基）丙酸甲酯 - 三氯甲烷
公开(公告)号：EP2759293A1
公开(公告)日：2014-07-30
申请号：EP13152687.3
申请日：2013-01-25
IPC分类号： A61K9/16 , A61K9/20 , A61K31/192 , A61P29/00
CPC分类号： A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K31/192
摘要： This invention relates to solid oral pharmaceutical compositions of (+)-(S)-2-(3-Benzoylphenyl)propionic acid tromethamine salt; a process of the manufacturing thereof and their use in the treatment of pain and inflammation.
摘要翻译： 本发明涉及（+） - （S）-2-（3-苯甲酰基苯基）丙酸氨基丁三醇盐的固体口服药物组合物。 其制造方法及其在治疗疼痛和炎症中的用途。
-
5.发明公开
公开(公告)号：EP2233131A1
公开(公告)日：2010-09-29
申请号：EP09155908.8
申请日：2009-03-23
CPC分类号： A61K9/2077 , A61K9/2018 , A61K9/2027 , A61K9/2054
摘要： The present invention relates to a pharmaceutical composition of entacapone, levodopa and carbidopa or phamiaceutically aceptable salts or hydrates thereof characterized in that it comprises a first mixture of entacapone and levodopa and a second mixture of levodopa and carbidopa. The invention also relates to a preparation method of said composition.
摘要翻译： 本发明涉及恩他卡朋，左旋多巴和卡比多巴或其药学上可接受的盐或水合物的药物组合物，其特征在于其包含恩他卡朋和左旋多巴的第一混合物和左旋多巴和卡比多巴的第二混合物。 本发明还涉及所述组合物的制备方法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
